© 2003 by Oxford University Press
Journal of the National Cancer Institute, Vol. 95, No. 9, 684-685,
May 7, 2003
© 2003 Oxford University Press
CORRESPONDENCE |
RESPONSE: Re: Trends in Use of Adjuvant Multi-Agent Chemotherapy and Tamoxifen for Breast Cancer in the United States: 19751999
Affiliations of authors: A. Mariotto, E. J. Feuer (Cancer Surveillance Research Program, Division of Cancer Control and Population Sciences), J. Abrams (Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis), National Cancer Institute, National Institutes of Health, Bethesda, MD.
Correspondence to: Angela Mariotto, Ph.D., National Cancer Institute, National Institutes of Health, 6166 Executive Blvd., Suite 504, MSC 8317, Bethesda, MD 208928317 (e-mail: mariotta@mail.nih.gov).
| The first 10% of the full text of this article appears below. |
We appreciate the findings and comments of Du, who used a different source of informationMedicare claims linked to the SEER1 databaseto estimate temporal changes in the use of adjuvant chemotherapy for breast cancer and obtained findings that are very similar to ours. He observes that both Mariotto et